OptimizeRx Co. (NASDAQ:OPRX) Receives Average Recommendation of “Moderate Buy” from Analysts

OptimizeRx Co. (NASDAQ:OPRX) has been given an average recommendation of “Moderate Buy” by the nine brokerages that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $9.06.

A number of brokerages have commented on OPRX. Stephens began coverage on shares of OptimizeRx in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price objective on the stock. B. Riley reduced their price target on OptimizeRx from $17.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, December 24th. Royal Bank of Canada restated a “sector perform” rating and set a $6.00 price objective (down from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. Lake Street Capital reiterated a “buy” rating and set a $11.00 target price on shares of OptimizeRx in a research note on Tuesday, December 24th. Finally, Barclays dropped their price target on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, November 14th.

Insider Transactions at OptimizeRx

In other OptimizeRx news, CEO William J. Febbo purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the purchase, the chief executive officer now directly owns 601,253 shares in the company, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its stake in OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of OptimizeRx during the fourth quarter valued at $51,000. Quest Partners LLC increased its position in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after acquiring an additional 9,739 shares during the last quarter. Barclays PLC grew its position in shares of OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after acquiring an additional 21,060 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in OptimizeRx in the second quarter worth about $282,000. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Trading Up 3.2 %

Shares of OPRX opened at $5.73 on Tuesday. OptimizeRx has a fifty-two week low of $3.78 and a fifty-two week high of $16.65. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a fifty day moving average of $5.22 and a two-hundred day moving average of $6.63. The company has a market capitalization of $105.55 million, a PE ratio of -4.31 and a beta of 1.36.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.